세계의 공캡슐 시장은 예측 기간 동안 7.4%의 연평균 복합 성장률(CAGR)을 나타낼 것으로 전망됩니다.
COVID-19의 유행은 시장 성장에 긍정적인 영향을 미칠 것으로 예상됩니다. BioPharma Ltd는 COVID-19 백신을 투여하기 위한 새로운 경구 캡슐을 개발했습니다.
시장의 성장을 뒷받침하는 주요 요인으로는 다른 약물전달 형태보다 캡슐의 인기가 높아지고 있는 것, 공캡슐 공급업체와 젤라틴 제조업자의 전략적 제휴가 증가하고 있는 것 등을 들 수 있습니다. 유엔의 '세계 고령화 인구: 2020 개정판'에 따르면 2050년에는 2020년 7억 2,700만 명에서 약 15억 명이 65세 이상 인구가 될 것으로 예상됩니다. 하지만 시장의 성장을 보완할 것으로 예상됩니다.
심혈관질환(CVD)은 세계적으로 매우 유행하고 있습니다. 2030년까지 2,360만 명 이상으로 증가할 것으로 예측되고 있습니다. 또, 2021년의 영국 심장 재단 센터에 의하면, 영국에서는 약 760만명이 심장·순환기 질환을 안고 생활했습니다. 매년, 75세 이하의 4만명 이상이 심장·순환기 질환으로 사망하고 있습니다. 세계의 심혈관 질환의 발생률의 높이는 효과적인 치료를 위한 심혈관 치료 수요를 급증시켜, 시장의 성장을 가속하고 있습니다.
게다가 COVID-19 팬데믹동안 미국 심장병학회와 캐나다 심혈관학회는 운동훈련과 식사 상담, 투약 관리, 금연 상담, 심리 사회적 평가 개입을 제공하는 재택 심장 재활 따라서 심장 서비스의 재도입을 위한 가이드 라인을 발행했습니다. 따라서 심장 재활 세션 증가는 COVID-19 팬데믹 기간 동안 연구 부문을 뒷받침할 것으로 예상됩니다.
또한 2019년 9월 Lupin은 고혈압 및 협심증의 빈도 감소를 치료하는 데 사용되는 프로프라놀롤 염산염 서방 캡슐에 대한 캐나다 보건 규제 당국으로부터 승인을 받았습니다.
공캡슐은 심장 치료의 맛을 마스킹하는 데 효과적이며 환자가 메스꺼움을 느끼는 것을 방지합니다. 따라서 CVD의 유병률이 증가함에 따라 심장 치료 수요도 증가합니다.
이 지역은 캡슐 기반의 영양 보조 식품 제제에 대한 선호도가 높아짐에 따라 큰 점유율을 차지하고 있습니다. 이 영양 보조 식품은 비만, 암, 관절염 등 주요 건강 문제의 예방에 도움이되므로 소비량이 증가하고 있습니다.
또한 미국에서 노인이 증가함에 따라 만성질환의 부담이 증가하고 있는 것도 북미 시장 성장의 주요인으로 여겨지고 있습니다. Survey on Dietary Supplements, 2019 보고서에 따르면 미국인의 77%가 영양 보충제를 섭취하고 있다고 응답했습니다. 보조 식품 소비량 전체의 76%를 차지한 다음 전문 보충제(40%), 허브와 식물성(39%), 스포츠 영양 보충제(28%), 체중 관리 보충제(17%)임이 밝혀졌습니다.
그러나, COVID-19의 대유행시에는 대부분의 식육가공시설이 폐쇄되었기 때문에 젤라틴의 입수가 제한되었습니다. 또한, 세계 각국의 국경에 있어서의 운송 제한 때문에 북미는 젤라틴 캡슐공급 체인에 심각한 영향을 받을 것으로 예상되어 동지역 시장 성장의 방해가 될 것으로 보여지고 있습니다.
게다가 미국과 캐나다는 발전하고 구조화된 의료제도를 가지고 있으며, 연구개발을 장려하고 있습니다.
세계의 주요 기업이 공캡슐의 대부분을 제조하고 있습니다. 더 많은 연구 자금과 더 나은 유통 시스템을 가진 시장 리더가 시장에서의 지위를 확립하고 있습니다. 또한, 아시아태평양에서는 공캡슐의 인지도가 높아져, 소수의 중소 기업이 대두해 왔습니다. 또한, 주요 기업은 경쟁 시장에서의 지위를 확보한다 이를 위해 전략적 제휴와 제품 출시에 관여하고 있습니다. 예를 들어, 2020년 10월, Lonza는 캡슐·건강 재료(CHI) 부문에 8,500만 스위스 프랑을 투자해, 캡슐 제조 능력을 연간 300억 캡슐 확대했습니다.
The Global Empty Capsules Market is expected to register a CAGR of 7.4% during the forecast period.
The COVID-19 pandemic is expected to positively impact the market's growth. As the development of strong immunity plays a vital role in fighting against viral infection, there has been an increasing demand for immunity boosters in the form of natural herbs and nutraceuticals. Apart from the basic hygienic practices, proper dietary and lifestyle behaviors are essential for preventing and treating respiratory viral diseases, such as COVID-19. As per the research article published in 2020, every COVID-19 patient should be screened for malnutrition on admission and assessed for serum vitamin D levels. Additionally, in March 2020, Stabilitech BioPharma Ltd developed a new oral capsule to deliver the COVID-19 vaccine. Thus, the COVID-19 pandemic is boosting the demand for nutraceuticals, which is expected to help the market to grow.
The key factors that boost the market's growth include a rise in the popularity of capsules over other drug delivery forms and an increase in strategic collaborations between empty capsule suppliers and gelatin manufacturers. Also, the growing geriatric population worldwide increases the demand for various therapy drugs and dietary supplements for better health outcomes. According to the United Nations, World Ageing Population: the 2020 Revision, by 2050, approximately 1.5 billion people are likely to be over 65 years, up from 727 million in 2020. In addition, rapid advancements in capsule delivery technologies are set to supplement the market's growth. However, ethical concerns, price fluctuations regarding gelatin materials, and stringent regulations in the pharmaceutical industry are expected to hamper the market growth.
Cardiovascular diseases (CVD) are highly prevalent globally. According to the World Health Organization 2019, an estimated 17.9 million people die due to cardiovascular diseases worldwide each year, and the number is expected to grow to more than 23.6 million by 2030. Additionally, as per the American Heart Association Research Report 2020, cardiovascular disease, listed as the underlying cause of death, accounts for nearly 2,353 deaths daily in the United States, which is an average of 1 death every 37 seconds. Also, according to the British Heart Foundation Centre, 2021, around 7.6 million people were living with heart and circulatory diseases in the United Kingdom. More than 40,000 people under the age of 75 years in the United Kingdom die from heart and circulatory diseases each year. The high incidence of cardiovascular diseases worldwide surges the demand for cardiovascular therapy drugs for effective treatment, thus driving the market's growth.
Additionally, during the COVID-19 pandemic, the American College of Cardiology and the Canadian Cardiovascular Society issued guidelines for the reintroduction of cardiac services, including home-based cardiac rehabilitation that provide exercise training and dietary counseling, medication management, tobacco cessation counseling, and psychosocial assessment interventions. Hence, the increasing cardiac rehabilitation sessions are expected to boost the studied segment during the COVID-19 pandemic.
Also, in September 2019, Lupin received approval from the Canadian health regulator for its Propranolol Hydrochloride extended-release capsules used to treat hypertension and decreased frequency of angina. The increasing product approvals are also expected to boost the segment over the forecast period.
Empty capsules are useful in masking the taste of cardiac therapy drugs, which prevents the patient from feeling nauseated. Hence, as the prevalence of CVDs increases, the demand for cardiac therapy drugs will also increase. This factor may positively impact the empty capsules market.
The region holds a major share due to the rising preference for capsule-based nutraceutical formulations. Since these nutraceuticals help prevent major health problems, such as obesity, cancer, and arthritis, their consumption has increased. Additionally, capsules are the most preferred solid oral dosage forms, and thus, the demand for empty capsules in the nutraceutical industry is high in the region.
Also, the growing burden of chronic diseases, along with the rising geriatric population in the United States, is considered a major factor for the growth of the market in North America. According to the Population Reference Bureau's Population Bulletin-Aging in the United States, the number of Americans aged 65 years and older is projected to nearly double from 52 million in 2018 to 95 million by 2060. Similarly, as per the CRN Consumer Survey on Dietary Supplements, 2019 report, 77% of Americans reported consuming dietary supplements. Also, the survey revealed that vitamins and minerals were the most common supplements consumed by the American population in 2019, accounting for 76% of total dietary supplement consumption, followed by specialty supplements (40%), herbals and botanicals (39%), sports nutrition supplements (28%), and weight management supplements (17 %) in 2019.
However, during the COVID-19 pandemic, most meat processing facilities were shut down, which limited the availability of gelatin. Additionally, due to the transport restrictions in the borders of various countries worldwide, North America is expected to be severely impacted on the supply chain of the gelatin capsule, which is expected to hamper the market's growth in the region.
Moreover, the United States and Canada have a developed and well-structured healthcare system, which encourages research and development. They also encourage global players to enter the United States and Canada. As a result, these countries enjoy the presence of many global market players. As the high demand is met by the presence of global players in the region, the market is further expected to grow over the forecast period.
Global key players are manufacturing the majority of empty capsules. Market leaders with more funds for research and a better distribution system have established their positions in the market. The empty capsules market is highly consolidated and consists of a few major players, including ACG Worldwide, Medi-Caps Ltd, LonzaGroup (Capsugel), Capscanada Corporation, and Bright Pharma Caps Inc. Moreover, Asia-Pacific is witnessing the emergence of a few small- and medium-sized players due to the rising awareness of empty capsules. Additionally, key players are involved in strategic alliances and product launches to secure their positions in the competitive market. For instance, in October 2020, Lonza invested CHF 85 million in its Capsules and Health Ingredients (CHI) division to expand its capsule manufacturing capacity by 30 billion capsules annually.